A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Summary

Novo Nordisk is developing the study medicine NNC0487-0111 to treat people living with type 2 diabetes and/or people living with overweight or obesity. The aim of this study is to see if blood levels of NNC0487-0111 are the same in people living with various degrees of reduced kidney function as for people with normal kidney function. Participants will be given one single injection by the study staff in a skinfold in their stomach using a pen device (NovoPen®4).

Timeline

Start

2024-08-20

Primary completion

2025-02-24

Completion

2025-03-05

Publications

• Oldenburg LIK, Haugaard SP, Karlsson T, Kegel-Hubner V, Parwez M, Wiingaard C, Flint A. Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. Diabetes Obes Metab. 2026 Jul 13. doi: 10.1111/dom.71096. Online ahead of print.

Drugs

Indications